2016_Head & Neck COURSE BOOK

BERIL-1 Key Secondary Endpoint: Overall Survival

100

80

60

Protocol-specified criteria for success were: HR ≤0.77 and posterior probability of (HR <1) >90.0%

40

20

12-month OS rate: 43% vs 33%

0 Probability of overall survival (%)

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28

Time (months)

Number of patients at risk 79 79 67 68 60 55 54 40

Buparlisib Placebo

44 30

39 25

26 21

20 14

12 10

7 7

6 4

2 3

1 3

1 1

0 0

Soulières D et al. ASCO 2016:Abstract 6008

June 5, 2016